Principal Financial Group Inc Insmed Inc Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

A detailed history of Principal Financial Group Inc transactions in Insmed Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 1,871,890 shares of INSM stock, worth $124 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

1,871,890

Previous 1,657,760 12.92%

Holding current value

$124 Million

Previous $111 Million 23.03%

% of portfolio

0.08%

Previous 0.07%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$62.0 - $79.01 $13.3 Million - $16.9 Million	214,130 Added 12.92%	1,871,890 $137 Million
Q2 2024 Jul 29, 2024	BUY	$22.0 - $69.71 $4.81 Million - $15.2 Million	218,480 Added 15.18%	1,657,760 $111 Million
Q1 2024 Apr 29, 2024	BUY	$25.72 - $29.94 $2.05 Million - $2.39 Million	79,717 Added 5.86%	1,439,280 $39 Million
Q4 2023 Feb 07, 2024	BUY	$23.42 - $31.74 $1.62 Million - $2.2 Million	69,281 Added 5.37%	1,359,563 $42.1 Million
Q3 2023 Nov 02, 2023	BUY	$19.86 - $26.93 $579,653 - $786,005	29,187 Added 2.31%	1,290,282 $32.6 Million
Q2 2023 Aug 07, 2023	BUY	$16.44 - $21.1 $132,555 - $170,129	8,063 Added 0.64%	1,261,095 $26.6 Million
Q1 2023 May 09, 2023	SELL	$16.26 - $21.73 $772,301 - $1.03 Million	-47,497 Reduced 3.65%	1,253,032 $21.4 Million
Q4 2022 Feb 09, 2023	SELL	$16.98 - $23.15 $448,543 - $611,530	-26,416 Reduced 1.99%	1,300,529 $26 Million
Q3 2022 Nov 09, 2022	BUY	$20.88 - $28.21 $5.89 Million - $7.96 Million	282,197 Added 27.01%	1,326,945 $28.6 Million
Q2 2022 Aug 10, 2022	BUY	$17.07 - $25.71 $4.14 Million - $6.24 Million	242,612 Added 30.25%	1,044,748 $20.6 Million
Q1 2022 May 09, 2022	BUY	$20.42 - $28.13 $398,863 - $549,463	19,533 Added 2.5%	802,136 $18.9 Million
Q4 2021 Feb 09, 2022	BUY	$25.89 - $33.45 $649,554 - $839,227	25,089 Added 3.31%	782,603 $21.3 Million
Q3 2021 Nov 09, 2021	BUY	$22.46 - $29.47 $802,316 - $1.05 Million	35,722 Added 4.95%	757,514 $20.9 Million
Q2 2021 Aug 10, 2021	BUY	$24.17 - $36.01 $3.99 Million - $5.95 Million	165,213 Added 29.68%	721,792 $20.5 Million
Q1 2021 May 10, 2021	BUY	$32.28 - $44.3 $1.6 Million - $2.2 Million	49,615 Added 9.79%	556,579 $19 Million
Q4 2020 Feb 08, 2021	SELL	$31.45 - $40.54 $942,776 - $1.22 Million	-29,977 Reduced 5.58%	506,964 $16.9 Million
Q3 2020 Nov 06, 2020	BUY	$26.0 - $34.5 $192,062 - $254,851	7,387 Added 1.39%	536,941 $17.3 Million
Q2 2020 Aug 05, 2020	BUY	$14.11 - $29.42 $2.99 Million - $6.23 Million	211,727 Added 66.62%	529,554 $14.6 Million
Q1 2020 May 12, 2020	BUY	$13.63 - $33.98 $1.36 Million - $3.4 Million	99,983 Added 45.9%	317,827 $5.1 Million
Q4 2019 Feb 05, 2020	BUY	$16.12 - $24.98 $12,331 - $19,109	765 Added 0.35%	217,844 $5.2 Million
Q3 2019 Nov 13, 2019	SELL	$15.49 - $25.78 $208,077 - $346,302	-13,433 Reduced 5.83%	217,079 $3.83 Million
Q2 2019 Aug 12, 2019	BUY	$23.0 - $32.19 $713,828 - $999,048	31,036 Added 15.56%	230,512 $5.9 Million
Q1 2019 May 10, 2019	BUY	$13.91 - $31.15 $776,595 - $1.74 Million	55,830 Added 38.87%	199,476 $5.8 Million
Q4 2018 Feb 14, 2019	SELL	$11.6 - $18.7 $60,563 - $97,632	-5,221 Reduced 3.51%	143,646 $1.89 Million
Q3 2018 Nov 14, 2018	SELL	$18.95 - $28.08 $7,712 - $11,428	-407 Reduced 0.27%	148,867 $3.01 Million
Q2 2018 Aug 13, 2018	SELL	$20.0 - $29.72 $127,740 - $189,821	-6,387 Reduced 4.1%	149,274 $0
Q1 2018 May 14, 2018	SELL	$21.69 - $32.99 $16,462 - $25,039	-759 Reduced 0.49%	155,661 $3.51 Million
Q4 2017 Feb 13, 2018	SELL	$26.43 - $31.78 $1.21 Million - $1.45 Million	-45,711 Reduced 22.61%	156,420 $4.88 Million
Q3 2017 Nov 02, 2017	BUY	$11.61 - $31.21 $2.35 Million - $6.31 Million	202,131	202,131 $6.31 Million

Others Institutions Holding INSM

# of Institutions

465

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $8.98B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Insmed Inc Transaction History